Edesa biotech, inc. (SBOT)
CashFlow / Yearly
Dec'18Sep'18Sep'17Sep'16Sep'15Aug'14Aug'13Aug'12
Net loss

-1,536

-5,038

-5,030

-5,026

-2,843

-8,439

-14,495

-5,529

Adjustments for:
Depreciation

1

-

-

-

-

-

-

-

Gain on disposition of fixed assets

0

-

-

-

-

-

-

-

Depreciation and amortization

-

188

179

-

-

-

-

-

Depreciation and amortization

-

-

-

149

159

158

124

112

Share-based compensation

81

154

115

259

267

956

786

1,923

Foreign exchange (gain) loss

-

-35

162

76

-653

-222

-95

10

(Gain) loss in fair value of warrant liability

-

-

-

-211

2,131

-2,533

-10,556

897

Transfer equipment to research and development

-

12

0

-

-

-

-

-

Change in equity investment in joint venture

-

-20

0

-

-

-

-

-

Change in working capital items:
Accounts and other receivable

-4

40

-84

-71

113

-121

192

-29

Prepaid expenses and other assets

-81

-36

-235

197

45

94

2

-4

Deferred share issuance costs

-

-

-

-

-

-60

62

0

Inventory

0

156

-181

-307

522

0

0

-

Deposits

-

-

-

-0

0

0

-

-

Accounts payable and accrued liabilities

79

172

-302

-33

77

106

29

292

Deferred revenue

-

-

-

-173

86

15

-127

127

Net cash used in operating activities

-1,288

-4,615

-4,699

-4,505

-4,412

-

-

-

Cash flows from investing activities:
Proceeds on sales of property and equipment

0

-

-

-

-

2

0

0

Cash acquired during reverse acquisition

0

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-4,266

-2,795

-3,947

Purchase of property and equipment

6

382

302

402

274

279

9

78

Purchase of short-term investments

-

9,083

5,005

11,995

13

5,468

0

0

Proceeds on sales and maturities of short-term investments

-

5,000

7,000

13,021

410

0

0

-

Contribution to joint venture

-

-

-

66

0

0

-

-

Net cash provided by (used in) investing activities

-6

-4,466

1,691

557

122

-

-

-

Cash flows from financing activities:
Payments for issuance costs

-

398

0

332

0

134

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-5,745

-9

-78

Proceeds from common shares subscribed

-

4,520

0

6,277

0

6,613

8,146

-

Proceeds from exercise of warrants

-

4,650

0

1,368

106

4,308

1,582

877

Net cash provided by financing activities

-

8,772

0

7,312

106

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-337

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net

-

-

-

-

-

-

-

0

Refund of deposit

-

-

-

-

-

-

1

0

Net cash provided by financing activities

-

-

-

-

-

10,787

9,730

877

Effect of exchange rate changes on cash and cash equivalents

-

-35

162

96

-629

-212

-64

2

Net change in cash and cash equivalents

-1,633

-345

-2,845

3,461

-4,812

563

6,860

-3,146

Supplemental disclosure of non-cash financing activities
Cash paid during the period for taxes

-

0

0

7

36

-

-

-

Non-cash assets acquired and liabilities assumed in reverse acquisition - See Note 11

0

-

-

-

-

-

-

-

Preferred shares exchanged for common shares in reverse acquisition

0

-

-

-

-

-

-

-

Issuance costs withheld from escrow proceeds

-

972

0

472

0

-

-

-

Loss on disposal of property, plant and equipment

-

-

-

-

-

-3

0

0

Impairment loss

-

-

-

-

-

90

0

0

Fair value of placement agent warrants

-

470

0

-

-

-

491

0